VCWA
ACXP icon

Vanguard Capital Wealth Advisors’s Acurx Pharmaceuticals ACXP Stock Holding History

Vanguard Capital Wealth Advisors’s Portfolio ACXP Stock Details ACXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,300
Closed -$23.5K – 135
2025
Q2 		$23.5K Sell
2,300
-1,075
-32% -$8.66K 0.02% 113
2025
Q1 		$26.3K Buy
+3,375
New +$45.5K 0.03% 110

Other funds holding ACXP

PFS
Prospect Financial Services Melville, New York $164M AUM 19.24% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NS
NBC Securities Birmingham, Alabama $1.33B AUM 24% 1-Year Est. Return
CPG
Cornerstone Planning Group Fairfield, New Jersey $749M AUM 17.97% 1-Year Est. Return
GWSG
GPS Wealth Strategies Group Centennial, Colorado $117M AUM 24.22% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Vanguard Capital Wealth Advisors's ACXP Position: Q3 2025 in Review

Vanguard Capital Wealth Advisors sold out of Acurx Pharmaceuticals (ACXP) in Q3 2025, closing a stake of 2,300 shares — an estimated $23.5K sold.

Vanguard Capital Wealth Advisors first reported a position in ACXP in Q1 2025 and held it in 2 quarters. The position peaked at $26.3K in Q1 2025. 16 funds tracked by Wall St. Rank hold ACXP as of Q3 2025.

  • Vanguard Capital Wealth Advisors reported no remaining Acurx Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Vanguard Capital Wealth Advisors sold 2,300 Acurx Pharmaceuticals shares in Q3 2025, an estimated $23.5K.
  • Vanguard Capital Wealth Advisors first reported a position in Acurx Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • Vanguard Capital Wealth Advisors's Acurx Pharmaceuticals position peaked at $26.3K in Q1 2025.
  • 16 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q3 2025.

Based on Vanguard Capital Wealth Advisors's 13F filing for Q3 2025, filed 30 Oct 2025.